|
|
Volumn , Issue , 2013, Pages
|
|
Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
MTOR PROTEIN, HUMAN;
PHOSPHATIDYLINOSITOL 3 KINASE;
PROTEIN KINASE B;
PROTEIN KINASE INHIBITOR;
TARGET OF RAPAMYCIN KINASE;
TUMOR MARKER;
ADVERSE EFFECTS;
ANIMAL;
ANTAGONISTS AND INHIBITORS;
DRUG EFFECTS;
ENZYMOLOGY;
GENETICS;
HUMAN;
METABOLISM;
MOLECULAR DIAGNOSIS;
MOLECULARLY TARGETED THERAPY;
NEOPLASMS;
PATHOLOGY;
PATIENT SELECTION;
PERSONALIZED MEDICINE;
PREDICTIVE VALUE;
SIGNAL TRANSDUCTION;
TREATMENT OUTCOME;
ANIMALS;
ANTINEOPLASTIC AGENTS;
HUMANS;
INDIVIDUALIZED MEDICINE;
MOLECULAR DIAGNOSTIC TECHNIQUES;
MOLECULAR TARGETED THERAPY;
NEOPLASMS;
PATIENT SELECTION;
PHOSPHATIDYLINOSITOL 3-KINASE;
PREDICTIVE VALUE OF TESTS;
PROTEIN KINASE INHIBITORS;
PROTO-ONCOGENE PROTEINS C-AKT;
SIGNAL TRANSDUCTION;
TOR SERINE-THREONINE KINASES;
TREATMENT OUTCOME;
TUMOR MARKERS, BIOLOGICAL;
|
|
EID: 84945990416
PISSN: None
EISSN: 15488756
Source Type: Journal
DOI: 10.1200/EdBook_AM.2013.33.e395 Document Type: Review |
|
Times cited : (73)
|
|
References (0)
|